Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ACELYRIN Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SLRN
Nasdaq
8731
https://www.acelyrin.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ACELYRIN Inc
Acelyrin Insiders Placed Bullish Bets Worth US$2.65m
- Apr 12th, 2024 1:05 pm
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
- Mar 28th, 2024 8:05 pm
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
- Mar 27th, 2024 8:01 pm
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
- Mar 20th, 2024 11:00 am
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
- Mar 11th, 2024 12:02 pm
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
- Mar 11th, 2024 12:00 pm
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
- Feb 15th, 2024 9:05 pm
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
- Dec 20th, 2023 9:30 pm
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
- Nov 27th, 2023 9:30 pm
Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing
- Nov 7th, 2023 10:11 pm
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
- Nov 7th, 2023 9:05 pm
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
- Nov 6th, 2023 12:00 pm
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
- Oct 31st, 2023 8:30 pm
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
- Oct 3rd, 2023 11:00 am
Arm, Instacart, Birkenstock ... the IPOs of 2023 and beyond
- Sep 27th, 2023 7:20 am
Why Acelyrin Stock Plummeted 59% This Week
- Sep 15th, 2023 9:39 pm
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
- Sep 11th, 2023 8:05 pm
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- Sep 6th, 2023 11:00 am
Billionaire Ken Griffin Pours Millions Into These 2 ‘Strong Buy’ Stocks — Here’s Why You Might Want to Ride His Coattails
- Aug 15th, 2023 11:22 pm
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
- Aug 14th, 2023 8:05 pm
Scroll